Advanced search
Publication Cover
Expert Review of Vaccines Volume 11, 2012 - Issue 7
Submit an article Journal homepage
30
Views
1
CrossRef citations to date
0
Altmetric
Key Paper Evaluation

Improved SIV DNA vaccine can be effectively used as a boost for Ad5 in prime–boost immunization strategy

Igor M Belyakov Michigan Nanotechnology Institute for Medicine and Biological Sciences, Department of Internal Medicine, Graduate Program in Immunology, University of Michigan, School of Medicine, 109 Zina Pitcher Place, BSRB, Room 4039, Ann Arbor, MI 48109, USA. [email protected]
Pages 787-790 | Published online: 09 Jan 2014

References

  • Hutnick NA, Myles DJ, Hirao L et al. An optimized SIV DNA vaccine can serve as a boost for Ad5 and provide partial protection from a high-dose SIVmac251 challenge. Vaccine 30(21), 3202–3208 (2012).
  • Belyakov IM, Ahlers JD. Mucosal immunity and HIV-1 infection: applications for mucosal AIDS vaccine development. Curr. Top. Microbiol. Immunol. 354, 157–179 (2012).
  • Ahlers JD, Belyakov IM. Lessons learned from natural infection: focusing on the design of protective T cell vaccines for HIV/AIDS. Trends Immunol. 31(3), 120–130 (2010).
  • Patel V, Valentin A, Kulkarni V et al. Long-lasting humoral and cellular immune responses and mucosal dissemination after intramuscular DNA immunization. Vaccine 28(30), 4827–4836 (2010).
  • Hutnick NA, Myles DJ, Bian CB, Muthumani K, Weiner DB. Selected approaches for increasing HIV DNA vaccine immunogenicity in vivo. Curr. Opin. Virol. 1(4), 233–240 (2011).
  • De Rosa SC, Thomas EP, Bui J et al.; National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network. HIV-DNA priming alters T cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectable. J. Immunol. 187(6), 3391–3401 (2011).
  • Shiver JW, Fu TM, Chen L et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415(6869), 331–335 (2002).
  • Casimiro DR, Wang F, Schleif WA et al. Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with DNA and recombinant adenoviral vaccine vectors expressing Gag. J. Virol. 79(24), 15547–15555 (2005).
  • Barouch DH, Liu J, Li H et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 482(7383), 89–93 (2012).
  • Sekaly RP. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J. Exp. Med. 205(1), 7–12 (2008).
  • Paris R, Bejrachandra S, Thongcharoen P et al.; Thai AIDS Vaccine Evaluation Group. HLA class II restriction of HIV-1 clade-specific neutralizing antibody responses in ethnic Thai recipients of the RV144 prime–boost vaccine combination of ALVAC-HIV and AIDSVAX(®) B/E. Vaccine 30(5), 832–836 (2012).
  • Veazey RS, DeMaria M, Chalifoux LV et al. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science 280(5362), 427–431 (1998).
  • Belyakov IM, Ahlers JD. What role does the route of immunization play in the generation of protective immunity against mucosal pathogens? J. Immunol. 183(11), 6883–6892 (2009).
  • Xiao P, Patterson LJ, Kuate S et al. Replicating adenovirus-simian immunodeficiency virus (SIV) recombinant priming and envelope protein boosting elicits localized, mucosal IgA immunity in rhesus macaques correlated with delayed acquisition following a repeated low-dose rectal SIV(mac251) challenge. J. Virol. 86(8), 4644–4657 (2012).
  • Lakhashe SK, Velu V, Sciaranghella G et al. Prime–boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges. Vaccine 29(34), 5611–5622 (2011).
  • Sui Y, Zhu Q, Gagnon S et al. Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques. Proc. Natl Acad. Sci. USA 107(21), 9843–9848 (2010).
  • Belyakov IM, Kuznetsov VA, Kelsall B et al. Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa. Blood 107(8), 3258–3264 (2006).
  • Bielinska AU, Janczak KW, Landers JJ, Markovitz DM, Montefiori DC, Baker JR Jr. Nasal immunization with a recombinant HIV gp120 and nanoemulsion adjuvant produces Th1 polarized responses and neutralizing antibodies to primary HIV type 1 isolates. AIDS Res. Hum. Retroviruses 24(2), 271–281 (2008).
  • Belyakov IM, Ahlers JD. Simultaneous approach using systemic, mucosal and transcutaneous routes of immunization for development of protective HIV-1 vaccines. Curr. Med. Chem. 18(26), 3953–3962 (2011).
  • Salazar-Gonzalez JF, Bailes E, Pham KT et al. Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J. Virol. 82(8), 3952–3970 (2008).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.